亞盛醫藥(06855.HK)抑制劑Lisaftoclax之客觀緩解率逾80%
亞盛醫藥(06855.HK)公布,公司四項入選2021美國臨床腫瘤學會(ASCO)年會的臨床研究的摘要已於今日在ASCO官網公佈。這四項研究涉及公司三個細胞凋亡管線品種,含兩項口頭報告。
其中Bcl-2抑制劑Lisaftoclax(APG-2575)的全球I期臨床研究成果顯示,APG-2575治療復發╱難治性(R/R)慢性淋巴細胞白血病╱小淋巴細胞淋巴瘤(CLL/SLL)患者的客觀緩解率(ORR)達85.7%,並顯示良好的耐受性與安全性。此外,MDM2抑制 Alrizomadlin(APG-115)聯合帕博利珠單抗應用於經免疫腫瘤藥物治療失敗的不可切除/轉移性黑色素瘤或晚期實體瘤患者的II期臨床研究表現出良好的前景。
數據顯示,APG-115聯合帕博利珠單抗治療對PD-1/PD-L1抑制劑耐藥黑色素瘤患者的疾病控制率(DCR)達60.9%,其中客觀緩解率(ORR)達到17.4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.